CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 144 enrolled
Drug / intervention
Ketamine +2 moredrug
Likely dose
Ketamine 2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05779657
NCT05779657Phase 3Completed

Efficacy of Combined Ketamine and Midazolam for Treatment of Generalized Convulsive Status Epilepticus in Children .

Sohag University·interventional·Posted Mar 22, 2023·Updated Oct 29, 2024

In Brief

A Phase 3 clinical trial evaluating Ketamine, Midazolam, and 1 other intervention for Generalized Convulsive Status Epilepticus. Completed, enrolled 144 participants across 1 site.

Detailed Summary

Generalized convulsive status epilepticus (GCSE) is a common neurological emergency in children. Benzodiazepines are the recommended first line antiseizure medication (ASMs), but they fail to control seizures in a third of cases. Combination of benzodiazepines with another ASM that has a different mechanism of action may be a promising option for faster control of GCSE. In this study, the investigators aim to evaluate the efficacy and safety of ketamine plus midazolam versus midazolam alone as first-line therapy of pediatric GCSE.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMar 22, 2023
Enrollment StartMar 21, 2023
Primary CompletionAug 26, 2024
Study CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.3 years ago

Interventions

Ketaminedrug

Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)

Midazolamdrug

Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes

Placebodrug

Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes